To specifically target TNF-alpha, monoclonal antibodies (mAbs) such as adalimumab, etanercept, and infliximab have been developed and extensively investigated in chronic autoimmune inflammatory disorders characterized by prominent pain symptoms, notably rheumatoid arthritis. This evidence concerns the gene TNF and rheumatoid arthritis.